PPT-Sexual Function Outcomes After Prostate Cancer Therapy

Know Your Goals John P Mulhall MD MSc FECSM FACS FRCSI Director Sexual amp Reproductive Medicine Urology Service Memorial Sloan Kettering Cancer Center NY USA Disclosures Grants . Chapter 4: Male Sexual Anatomy & Physiology. The . Penis: internal anatomy. Consists of nerves, blood vessels, fibrous tissue & spongy tissue; no bones!. Interior portion of the penis is the . Alexandre . Iscaife. ; Denis Reis Morais; Sabrina Thalita Reis; Nayara Izabel Viana, . Andre. . Bordini. ; Daniele . Janolli. ; Nelson . Dip. ; Miguel . Srougi. ; Katia Ramos Moreira Leite . Laboratory of Medical Research – LIM 55, Urology, University of Sao Paulo, Sao Paulo, Brazil. Treatment: . Is there an Analogy to Female Pelvic Cancer?. Ege Can Serefoglu, MD, . FECSM. UroKlinik. , . Istanbul. , . Turkey. 1. Outline. Cancer. . Treatment. . and. . Sexual. . Dysfunction. Prostate Cancer and Sex. ADVANCED PROSTATE CANCER: BONE ISSUES AND METASTASES Samuel Denmeade, MD Professor of Oncology, Urology and Pharmacology The Johns Hopkins University School of Medicine Castrate-sensitive Non-Metastatic Background A National Institutes of Health NIH panel that convened in 2011 recommended that AS151a strategy with curative intent that involves regular monitoring of PSA levels and repeat biopsies151sh Andrew J Armstrong MD . ScM. FACP. National Alliance of State Prostate Cancer Coalitions Webinar Series . November 2020. Professor of Medicine and Surgery, Pharmacology and Cancer Biology. Director of Research, Duke Cancer Institute . Investigations for Prostate cancer Presentation: Diagnosis: Risk stratification (Ref) : Low risk PSA 0, Gleason score 6 (ISUP 1), DRE showing cT1 - T2a Intermediate risk: PSA 10 - 20, Thomas M. Schroeder, MD November 14. th. , 2020. Outline. Overview of All Localized Treatments for Prostate Cancer. Interesting Important Recent Developments. Active Surveillance, Radiation, or Surgery. Sorting Out the Androgen Deprivation Therapy Options for Locally Advanced . CSPC. Supported by an educational grant from Astellas and Pfizer, Inc.. EPISODE 3. Cora N. Sternberg MD, FACP. Clinical Director, . . Using PSMA-PET for accurate staging in biochemical recurrent metastatic prostate cancer. . Case courtesy of Associate Professor Yao ZHU, Fudan University, Shanghai Cancer Center. Photo by . Hobi. Victoria . Sinibaldi. , RN, MS, CS, CANP, BC. Daniel P . Petrylak. , MD. . Disclosures for . Ms. . Sinibaldi. No financial interests or affiliations to disclose. Disclosures for Dr . Petrylak. Consulting Agreements. By: Ishan Parikh. Symptoms. Be on the look out for…. “stop-and-go” flow of urine. Sudden urges to urinate. Frequent urination (esp. at nights). Trouble starting urination. Trouble with emptying bladder completely. Dr Marie-Pier St-Laurent, MD, FRCSC. Urologic-Oncology fellow, UBC. Research scientist, Vancouver Prostate Centre. Honorarium: Bayer, PCSC. As a urologist, I am biased towards prostate cancer screening.. NASPCC 10-13-18. Ronald Chen, MD MPH. Associate Professor, Radiation Oncology. University of North Carolina – Chapel Hill. Associate Director, UNC Lineberger Comprehensive Cancer Center. Disclosures.